Psychiatry News

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.

Drug overdose deaths in the United States decreased in 2023 for the first time in half a decade, preliminary CDC data showed.

Any doctor seeing patients has had to field questions unrelated to their specialty.

Beta-blocker therapy did not reduce negative intrusive thoughts or anxiety among cancer survivors, according to results of an emulated trials analysis published in BMC Cancer.

For those with epilepsy who may become pregnant and their potential offspring, medications must optimize seizure control as well as outcomes for the fetus, according to new guidelines presented in Neurology.

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

Persistent shorter sleep durations during childhood were associated with a greater risk of psychosis disorder and psychotic episodes during early adulthood, a study in JAMA Psychiatry showed.

NEW YORK — Administering marijuana to patients who may benefit from its therapeutic properties is a “complex sociopolitical and medical” issue, Brody Montoya, DO, says in this Healio video from the American Psychiatric Association annual meeting.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.